Supernus Pharmaceuticals, Inc. (SUPN) is a publicly traded Healthcare sector company. As of May 21, 2026, SUPN trades at $48.47 with a market cap of $2.81B and a P/E ratio of -96.00. SUPN moved +2.27% today. Year to date, SUPN is -1.44%; over the trailing twelve months it is +46.66%. Its 52-week range spans $29.16 to $59.68. Analyst consensus is strong buy with an average price target of $63.17. Rallies surfaces SUPN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for SUPN combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $48.47 |
| Market Cap | $2.81B |
| P/E Ratio | -96.00 |
| EPS | $-0.51 |
| Dividend Yield | 0.00% |
| 52-Week High | $59.68 |
| 52-Week Low | $29.16 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $776.83M |
| Net Income | $-29.02M |
| Gross Margin | 89.42% |
6 analysts cover SUPN: 0 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $63.17.